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One third of the world’s population is affected by Tuberculosis (TB), a disease 
caused by infection with Mycobacterium tuberculosis. The emergence of multidrug-
resistant MtB makes this disease a major public health concern. New agents are needed to 
treat TB infections in a manner that circumvents existing pathways of resistance. One 
strategy is to target the organism at the translational level by inhibiting vital modifications 
of RNA. One gene responsible for these modifications is the tRNA (guanosine-1)-
methyltransferase, trmD, which has been shown to be essential in several bacteria. The 
eukaryotic and bacterial m
1
G methyltransferases are structurally dissimilar, making this 
enzyme an ideal target for selective anti-TB agents.  
 
viii 
One strategy for TrmD inhibitor design is to target the catalytic center of the 
enzyme. Existing inhibitors such as Sinefungin exhibit poor selectivity due to the 
substrate’s role, SAM, as a universal methyl donor in many biological processes. 
Structure/activity relationships for inhibitory compounds are sparse, impeding the design 
of novel antimicrobials. Crystallographic data would identify molecular features unique to 
TrmD, and allow design of agents complimentary to the TrmD active site with minimal 
differential toxicity. Presently, no crystal structure for Mycobacterium tuberculosis TrmD 
exists. 
 
As a first step in this direction, the MtB gene has been cloned and expressed by 
using a His-tagged T7 expression vector. The recombinant protein was characterized 
through kinetic and preliminary inhibitor assays. The native enzyme displays a mass of 50 
kDa, proving this enzyme is a dimer of two identical subunits. This is similar to data found 
on other TrmD orthologs. Crystallization of MtB TrmD has been achieved and preliminary 
x-ray diffraction studies conducted.
  
Chapter 1 
1.1 General Introduction to Mycobacterium Tuberculosis 
 
 Tuberculosis (TB) is the most common cause of infectious disease–related 
mortality worldwide. According to the World Health Organization (WHO), one third of the 
world's population has been exposed to the tuberculosis pathogen (1). Although TB rates 
are decreasing in the United States, the disease is becoming more common in many parts 
of the world. In addition, the prevalence of drug-resistant TB is also increasing worldwide. 
Co-infection with HIV has been an important factor in the emergence and spread of 
resistance (2). New TB treatments are being developed (3) and new TB vaccines are 
currently under investigation (4).  
 
 Tuberculosis is a communicable disease caused by the Mycobacterium tuberculosis 
(MtB) bacterium, which is the causative agent of human tuberculosis. It is an aerobic 
bacterium that divides every 16 to 20 hours, an extremely slow rate compared with other 
bacteria, which usually divide in less than an hour (5). Humans are the only known 
reservoir. The pathogenicity of M. tuberculosis relies on its ability to survive and persist 
within the host macrophage cells during infection. The pathogen primarily infects the 
mammalian respiratory system but can also attack any part of the body such as the kidney, 
spine and brain (5). If not treated properly, TB is fatal. The mode of transmission is 
through air from one person to another. A person with active TB disease of the lungs or 
throat infects people around them. Two types of conditions exist: latent and active TB. In 
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latent, the pathogen lives in one’s body without showing symptoms in the individual. In 
active, the person shows symptoms and infects others nearby. Annually, 8 million people 
become ill with tuberculosis, and 2 million people die from the disease worldwide. In 
2004, approximately 14.6 million people had active TB disease with 9 million new cases. 
The annual incidence rate varies from 356 per 100,000 in Africa to 41 per 100,000 in the 
Americas (6). Tuberculosis is the world's greatest infectious killer of women of 
reproductive age and the leading cause of death among people with HIV/AIDS. It is 
responsible for three million deaths annually, more than AIDS, malaria and other tropical 
diseases combined. Tuberculosis is one of the three primary diseases of poverty along with 
AIDS and malaria (1). 
 TB was once thought to be virtually eradicated in developed countries due to 
development of novel antimycobacterial drugs and improved public health management. 
However, the recent resurgence of multi-drug resistant (MDR) strains of TB and the 
immunocompromising nature of the HIV virus, which allows TB to thrive and spread in 
the host, make the statistics associated with TB frightening. This has led to the WHO 
recognizing TB as a potential global emergency for human health. After the discovery of 
the first anti-tubercular drug streptomycin in 1943, followed by Isoniazid (INH), Para-
Amino Salicyclic Acid and Rifampicin (RIF) in the early 1960s, the drug regime for TB 
has remained unchanged for the past 50 years (7). Patients with drug resistance are much 
harder to treat. Therefore, it is of importance to identify genes and pathways that are 
involved in the survival and persistence of M. tuberculosis within cells. Thus, this indicates 
11 
the urgent need for new anti-TB drugs and subsequent discovery of novel drug targets in 
TB. 
1.2 Characteristics of Methyltransferases 
 A methyltransferase (Mtase) is a type of transferase enzyme which transfers a 
methyl group from a donor to an acceptor. A considerable number of the methyl groups in 
cell metabolites accept a methyl group by an ATP-activated form of methionine, S-
adenosyl-L-methionine (AdoMet) (8). Mtases use a 
reactive methyl group bound to sulfur in S-adenosyl 
methionine as the methyl donor (Figure 1). It is now 
known that DNA, RNA, proteins, lipids and 
polysaccharides are methylated by AdoMet-dependent 
methyltransferases (8).   
 
 
 All types of cellular RNAs contain modified nucleosides, but the largest number 
and greatest variety are found in transfer RNAs (tRNAs) (9). tRNAs contain site-specific 
base and backbone modifications that are important in overall structural stability and 
function (10). One important modification enzyme is the 
m
1
G37 tRNA methyltransferase which methylates the N1 
group of guanine at position 37 of tRNA using S-
adenosylmethionine (Figure 2). Methylation of G37 requires 
Figure 1: Structure of AdoMet. Sulfur 
bound to methyl group that is donated 
to tRNA. AdoMet is highlighted in 
yellow. 
 
Figure 2: Guanine 37 of tRNA 
(Anticodon Loop) 
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a purine (Guanine) at position 36 of tRNA.  
 m
1
G37 tRNA methyltransferase is found in all three domains of life, Eubacteria, 
Eukarya and Archaea and is denoted TrmD, Trm5 and aTrm5 respectively (11, 12). This 
enzyme is also present in organelles (mitochondria and chloroplasts) and in the bacteria 
Mycoplasma spp, which have the smallest genomes known to date (11). Mtase participates 
in the translational phase of protein synthesis by maintaining proper codon:anticodon 
alignment. Methylation of Guanine at position 37, near the 3’ of the anticodon nucleotides 
34, 35, 36, provides a steric hindrance to further Watson-Crick base pairing between tRNA 
and mRNA molecules (Figure 3).  Thus, it prevents the occurrence of frame shift events 
which would result in the formation of truncated or aberrant proteins (13, 14). Hence, it 
reduces frame shift errors during translation. Previous experiments have proven this is an 
essential function step for yeast and gram negative bacteria (15-17).  Studies performed by 
Björk et al. (11, 14, 15) reported that the TrmD protein plays a vital role in maintaining the 
proper reading frame during translation. Having either a mutant enzyme or trmD gene 
knockout will cause the bacteria to grow 
more slowly or even be lethal in some 
organisms (17). The importance of the 
m
1
G37 modification in the overall 
quality of protein synthesis emphasizes  
                                                                                 its conservation throughout evolution.  
 
 
a. b. 
Figure 3: Watson-Crick base pairing. A.) Nucleotides 
are base pairing with each other. B.) Nucleotides cannot 
base pair due to methylation. 
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1.3 TrmD Structure 
 trmD is a member of the SPOUT methyltransferases which are a class of S-
adenosylmethionine dependent enzymes characterized by an unusual α/β fold with a deep 
topological knot (18,19). This knot constitutes a major portion of the AdoMet binding 
pocket and is buried deep in the protein. Most S-adenosylmethionine dependent 
methyltransferases, including trmD, belong to the Class I family which contains the 
recognized AdoMet binding pocket known as the Rossman fold (20). Substrates for Class I 
methyltransferases include DNA, RNA, small molecules and other proteins (21).  
 The Holmes laboratory has performed extensive studies on the E. Coli TrmD and 
the structure has a 38% sequence homology identity to Mycobacterium tuberculosis trmD 
(Table 1).  Thus, it will be used as a form of comparison to Mycobacterium tuberculosis 
trmD. X-ray crystallography of the E. Coli enzyme reveals two binding sites for AdoMet 
which are deeply buried within the interior of the enzyme (22). The E. coli monomer of 
trmD consists of two discrete domains, the C-terminal domain and the AdoMet binding 
domain, connected by an extended flexible linker region of 11 residues (Figure 4). Five 
major parallel beta strands and a sixth short strand extending the sheet on one edge are 
inserted between layers of helices and make up the core of the domain (Figure 5). The 
AdoMet binding site is found at one end of the beta sheet and is a central part of a deep 
trefoil knot structure. Beta sheets are built from a central N-terminal (NT) beta strand β1, 
with β2 lying along side of β1, and β4 as the next strand in the sheet which are parallel to 
each other (Figure 5). More than one-half of the enzyme is involved in the knot structure, 
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which forms the AdoMet-binding site or active site (22). The active site is located in the 
AdoMet Domain near the β3, β5 and α5 strands. The active site is located in between the N 
and C terminal domains of two monomers. This observation suggests that the dimer edges 
interact (22).  The substrate, AdoMet, is encircled in a deep pocket surrounded by the 
adenine-binding loop, the β3 and β5 strand, and the loop leading into helix α5 (Figure 5). 
The loop structure called “the halo” extends between α3 and α5. The C-terminal domain 
(CT) consists of alpha coils (α7- α10) connected to the AdoMet domain by a flexible linker 
(Figure 5). The substrate takes into a bent conformation in the binding site. The adenine 
binding region curves around the adenine ring (Figure 5).  E. coli structure analysis 
suggests that significant conformational changes must occur for the substrate binding and 
catalytic turnover (22).  
 Using a program entitled Chimera®, depictions of the active site interacting with 
AdoMet was generated. At first glance, certain amino acids appear to interact through 
hydrogen-bonds with the AdoMet substrate. The amino acids involved include Tyrosine 
134, Glycine 136, Leucine 138, Glycine 140, Glycine 141, Tyrosine 86 and Leucine 87. 
Hydrogen bonds between Glycine 134, Tyrosine 136 and Leucine 138 to the AdoMet 
substrate help to stabilize the cofactor in place. Additionally, Glycine 140, Tyrosine 86 and 
Leucine 87 interact with the ribose of AdoMet to tether it in place (Figure 6).  The ribose 
moiety of the AdoMet twists in a conformation that results in the methionine region that is 
perpendicular to the adenine ring. 
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Figure 4: Model of E. coli TrmD (pdb 1P9P) generated by Chimera® displaying dimer 
structure with AdoMet domain, C-terminal domain, AdoMet binding site, Adenine binding 
loop and Halo region. Homologous monomers are indicated in red and blue ribbons. The 
substrate, AdoMet, is represented by red ball & stick structures in each monomer.  
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Figure 5: Model of a monomer of E. coli TrmD (pdb 1P9P) generated by Chimera® 
displaying monomer structure with alpha 1-10 and beta 1-5 strands, AdoMet and C-
terminal domains (CT), AdoMet molecule bound, flexible linker region and Halo region. 
NT stands for the N-terminal domain. AdoMet molecule is represented by gray spheres.  
AdoMet 
17 
 
Figure 6: Interaction of amino acids in active site with AdoMet colored green. Pink lines 
indicate where hydrogen bonding occurs between amino acids. Image produced using 
Chimera®. 
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Currently, six crystallographic TrmD protein structures have been done. These 
structures correspond to: Anaplasma phagocytophilum, Aquifex aeolicus, Bartonella 
henselae, Escherichia coli, Haemophilus influenza and Staphylococcus aureus. An amino 
acid sequence alignment between these organisms and Mycobacterium tuberculosis TrmD 
was performed using a program entitled “Clustalw” (Figure 7).  From this alignment 
percent sequence homologies were calculated between the organisms and Mycobacterium 
tuberculosis TrmD (Table 1). Bartonella henselae TrmD has a 42.9% sequence homology 
to Mycobacterium tuberculosis TrmD, which is the highest percent sequence homology. 
Anaplasma phagocytophilum TrmD has a 42.7% sequence homology. Aquifex aeolicus 
TrmD has the lowest sequence homology with a 32.6%. Escherichia coli TrmD has a 
sequence homology of 38% (Table 1). Sequence alignment of TrmD proteins of known 
structures indicates that TrmD from B. henselae and A. phagocytophilum have the highest 
shared sequence identity with MtB TrmD. Furthermore, B. henselae contains structural 
regions that were overlapping with MtB TrmD and that were not resolved in the other 
crystal structures. The length of the B. henselae TrmD (233 amino acids) is almost 
identical to the M. tuberculosis TrmD (230 amino acids). Thus, the B. henselaet TrmD is 
the best choice for the phasing model, since it includes most of the protein, and has a high 
percent homology with M. tuberculosis TrmD. A multiple alignment TrmD diaphragm was 
generated using Chimera with Anaplasma phagocytophilum (yellow), Bartonella henselae 
(olive green), Escherichia coli (purple), Haemophilus influenza (blue) and Staphylococcus 
aureus (orange) (Figure 8). The flexible linker region is yet to be resolved in the pdb 
structures.  
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Bartonella       -----------------SMKFQAR--------VLTLYPEMFPGFLGCSLAGQALKQGIWS 35 
Anaplasma        -----------------TLEAQTQGPGSMIFNVLTIFPQMFPGPLGVSNLGSALKKGLWT 53 
trmDz            --------------------MRID--------IVTIFPACLD-PLRQSLPGKAIESGLVD 31 
E.Coli           --------------------MWIG--------IISLFPEMFRAITDYGVTGRAVKNGLLS 32 
Influenzae       ----------SSGLVPRGSHMWIG--------VISLFPEMFKAITEFGVTGRAVKHNLLK 52 
StaphAureus      ----------SSGVDLGTENLYFQSN-AMKIDYLTLFPEMFDGVLNHSIMKRAQENNKLQ 56 
Aquifex          ---------------MSSNPLRFF--------VLTIFPHIISCYSEYGIVKQAIKKGKVE 37 
                                                 ::::*  :      .    * : .    
 
Bartonella       LETVQIRDFALDKHHSVDDTPAGGGAGMVMRADVLAAALDSCPNDSP----RLLMSPRGR 91 
Anaplasma        LNVFDIRAFANNKHNTVDDTPYGGGPGMLLRADVLGRCIDEVLSLHPN-TKLMFTSPRGV 112 
trmDz            LNVHDLRRWTHDVHHSVDDAPYGGGPGMVMKAPVWGEALDEICSSET---LLIVPTPAGV 88 
E.Coli           IQSWSPRDFTHDRHRTVDDRPYGGGPGMLMMVQPLRDAIHAAKAAAGEGAKVIYLSPQGR 92 
Influenzae       VECWNPRDFTFDKHKTVDDRPYGGGPGMLMMVQPLRDAIHTAKAAAGEGAKVIYLSPQGR 112 
StaphAureus      INTVNFRDYAINKHNQVDDYPYGGGQGMVLKPEPVFNAMEDLDVTEQA--RVILMCPQGE 114 
Aquifex          VYPIDLREFAP--KGQVDDVPYGGLPGMVLKPEPIYEAYDYVVENYGK-PFVLITEPWGE 94 
                 :   . * ::   :  *** * **  **::       . .            :   * *  
 
Bartonella       LLNQAYARSLARSSGVTLVCGRFEGVDERIIEAR----ELEEVSIGDYILSGGETAALVL 147 
Anaplasma        SFTQDIARQTMNFDNITLLCGRFEGIDERVVDFY----KLQEVSIGDYVLSGGELAAMVI 168 
trmDz            LFTQATAQRWTTESHLVFACGRYEGIDQRVVQDAARRMRVEEVSIGDYVLPGGESAAVVM 148 
E.Coli           KLDQAGVSELATNQKLILVCGRYEGIDERVIQTE----IDEEWSIGDYVLSGGELPAMTL 148 
Influenzae       KLDQGGVTELAQNQKLILVCGRYEGIDERLIQTE----IDEEWSIGDYVLTGGELPAMTL 168 
StaphAureus      PFSHQKAVELSKADHIVFICGHYEGYDERIRTHL----VTDEISMGDYVLTGGELPAMTM 170 
Aquifex          KLNQKLVNELSKKERIMIICGRYEGVDERVKKIV-----DMEISLGDFILSGGEIVALAV 149 
                  : :  .      . : : **::** *:*:           * *:**::*.***  *:.: 
 
Bartonella       LDAIVRLLPGVMGNEISAKCESFEN---GLLEHPQYTRPAVFEGRGIPPVLTSGHHKAIA 204 
Anaplasma        IDTCVRMVPGVIGNAESLKQESME----GSLEYPQYTRPASWKGMEVPEVLLTGNHGEIE 224 
trmDz            VEAVLRLLAGVLGNPASHQDDSHSTGLDGLLEGPSYTRPASWRGLDVPEVLLSGDHARIA 208 
E.Coli           IDSVSRFIPGVLGHEASATEDSFAE---GLLDCPHYTRPEVLEGMEVPPVLLSGNHAEIR 205 
Influenzae       IDAVARFIPGVLGKQASAEEDSFAD---GLLDCPHYTRPEVLEGLTVPPVLMSGHHEEIR 225 
StaphAureus      TDAIVRLIPGVLGNEQSHQDDSFSD---GLLEFPQYTRPREFKGLTVPDVLLSGNHANID 227 
Aquifex          IDAVSRVLPGVLSEPQSIQEDSFQN---RWLGYPVYTRPREYRGMKVPEELLSGHHKLIE 206 
                  ::  *.:.**:..  *   :*        *  * ****   .*  :*  * :*.*  *  
 
Bartonella       NWRQQQAESLTRQRRPDLY-ALYNKNRQKT--------------------- 233 
Anaplasma        KWRRNASLSITAARRPDLLKDRYGENDVE---------------------- 253 
trmDz            AWRREVSLQRTRERRPDLS---HPD-------------------------- 230 
E.Coli           RWRLKQSLGRTWLRRPELLENLALTEEQARLLAEFKTEHAQQQHKHDGMA- 255 
Influenzae       KWRLKQSLQRTWLRRPELLEGLALTDEQRKLLKEAQAEHNSLEHHHHHH-- 274 
StaphAureus      AWRHEQKLIRTYNKRPDLIEKYPLTNADKQILERYKIGLKKG--------- 269 
Aquifex          LWKLWHRIENTVKKRPDLIPKDLTELEKDILNSILSGKSFKEWLKEHKHLL 257 
                  *:       *  :**:*    
 
 
Figure 7: Amino Acid Sequence Alignment generated by program ClustalW of Anaplasma 
phagocytophilum, Aquifex aeolicus, Bartonella henselae, Escherichia coli, Haemophilus 
influenza and Staphylococcus aureus. The amino acids in red depict residues that displayed 
no electron densities in the crystal structure, which therefore must be very mobile regions 
of the proteins Some regions of these proteins are completely conserved such as the halo 
region. “*” means that the residues or nucleotides in that column are identical in all 
sequences in the alignment. ":" means that conserved substitutions have been observed. "." 
means that semi-conserved substitutions are observed. 
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Organism Percent Sequence Homology 
Bartonella henselae 42.9% 
Anaplasma phagocytophilum 42.7% 
Staphylococcus aureus 39.0% 
Escherichia coli 38.0% 
Haemophilus influenza 34.3% 
Aquifex aeolicus 32.6% 
 
Table 1: Percent Sequence Homology of TmD organisms to Mycobacterium Tuberculosis 
TrmD. 
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Figure 8: Alignment of TrmD organisms. The flexible linker region is unsolved in the pdb 
files. The following organisms are shown: Anaplasma phagocytophilum (yellow), 
Bartonella henselae (olive green), Escherichia coli (purple), Haemophilus influenza (blue) 
and Staphylococcus aureus (orange). Image produced using Chimera® 
22 
  
 
 
Figure 9: tRNA Anti-codon arm and Loop 
 
 
 
 
 
 
 
G (36) 
G (37) 
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1.4 Mechanism of Action 
 AdoMet dependent methyltransferases catalyze the transfer of the methyl group in 
a SN
2 
type reaction scheme, which allows for only one stereoisomeric product to form due 
to formation of a triplet state intermediate (Figure 10). The transfer occurs via a 
nucleophilic attack at a sp
3
 hybridized carbon, 
which often requires a general base catalyst, 
followed by a thioester transition state, and the 
release of the product S-adenosylhomocysteine. 
Methylation of the N1 position of guanine is 
believed to occur via a deprotonation by a                              
                                                                     general base catalyst on the N1 nitrogen. tRNA 
(guanonsine-N1) methyltransferase (TrmD) is the product of trmD genes which catalyze 
the transfer of the methyl group of AdoMet to the N1 position of guanine 37 adjacent the 
anticodon loop (Figure 9). These proteins methylate only transfer RNAs that recognize 
codons starting with cytosine, and therefore methylate only tRNA species with guanine at 
positions 37 and 36. AdoMet is the product of S-adenosylmethionine synthetase, which 
transfers the adenosyl moiety of ATP to the amino acid methionine. After transfer of its 
methyl group, AdoMet becomes S-adenosylhomocysteine (AdoHcy). Further metabolism 
of the product results in the cleavage of the adenosine moiety to form homocysteine. 
Homocysteine can either be recycled or eventually broken down into the amino acid 
cysteine within the cell. Methylation of Guanine at position 37, near the 3’ of the anticodon 
nucleotides 34, 35, 36, provides a steric hindrance to further Watson-Crick base pairing 
Figure 10:  m1G37 methylation 
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between tRNA and mRNA molecules (Figure 11).  Thus, it prevents the occurrence of 
frame shift mutations which would result in the formation of truncated or aberrant proteins 
(13, 14). Hence, it reduces frame shift errors during translation. 
 
 
Figure 11: Frame shifting prevented during protein translation 
 
 
1.5 Inhibition of trmD  
One potential target site for TrmD inhibitors is the SAM binding site. The presence 
of an inactive compound in the cofactor site will abrogate SAM binding and deprive the 
enzyme of its methyl donor. Several inhibitors modeled after SAM have been designed and 
evaluated, however these agents have been found to be non-selective. This non-selectivity 
is a major drawback because SAM is utilized as a universal methyl donor in many 
m 1G37
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codon codon codon
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biological processes (23); hence inhibition of SAM binding will have broad toxicity. 
Furthermore, the structures considered in these studies are not diverse and hence structure 
activity relationships are poorly defined as of yet. One strategy to achieve selectivity and 
high affinity is through structure based design. However, this requires the crystal structure 
of TrmD. Crystallographic data will permit identification of molecular features unique to 
TrmD, and thus the design of agents complimentary to the TrmD active site(s).  This 
strategy can be extended through the use of bisubstrate analogues (24); which bridge 
between the SAM and nucleoside sites, affording more features to exploit for modification.  
The urgent need to develop new drugs due stems from the fact that resistance to 
antibacterial drugs is becoming more common. Drug design strategies currently underway 
to inhibit tRNA methyltransferase include making analogues of SAM or targeting the 
SAM binding site. In a study performed by Barchas and Deguchi (25) it was found that S-
adenosyl-L-homocysteine (L-SAH), analogue of SAM, is a potent inhibitor of several 
methyltransferases including tRNA methyltransferase (26).
 
This demethylated product 
inhibits many SAM-dependent methyltransferases (27). Analogues of AdoMet that either 
compete with substrate and/or prevent methylation can be a possible way to inactivate the 
enzyme. Mechanism based inhibition that targets the active site of SAM can perhaps 
irreversibly degrade the enzyme. Successful DNA methyltransferase inhibitors have been 
found. Azacitidine, an approved DNA methyltransferase inhibitor, has also been found to 
inhibit RNA and protein methyltransferases (28). This drug acts by incorporating itself into 
DNA and preventing methylation by the methyltranferase. Subsequently, cell death is 
induced since DNA synthesis is obstructed (28).  
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Selectivity is the main challenge in developing inhibitors for methyltransferases. 
SAM is a universal methyl donor recognized by many biological processes. Developing a 
compound that only targets TrmD is the major hurdle to overcome. Additionally in 
understanding mechanisms based inhibition, crystallographic structures of enzymes need 
to be determined. Drug potency is also another issue to consider. Yet, the benefit of 
designing a drug that effectively targets proliferation of a disease has extraordinary 
implications. One third of the world’s population infected with TB will be dramatically 
impacted. A successful RNA MTase inhibitor may also affect DNA and protein Mtase.  
Furthermore, selectivity over mechanistically similar enzymes can be achieved using the 
crystallographic data to tune the drug to the TrmD active site. 
 
1.6 Introduction to Enzyme Kinetics 
   
To determine the maximum rate of an enzyme-mediated reaction, a series of 
experiments are carried out with varying substrate concentrations [S]. The Michaelis-
Menton equation can then be used to determine the constants for the data sets.  
The Michaelis-Menten equation relates two observable parameters, the initial 
velocity of an enzymatic reaction (Vo) and the substrate concentration [S], 
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From the Michaelis-Menton equation it is clear that Vo and [S] do not exist in a 
linear relationship. One way to determine Km and Vmax is through the use of a Line-Weaver 
Burke plot, in which the 1/Vo is in a linear relationship with 1/[S]. 
 
The reciprocals of the experimental parameters Vo, [S] may be calculated and a linear fit 
performed in which the y intercept is 1/Vmax and the x intercept is -1/Km. This method is 
problematic since it represents a linearization of an inherently nonlinear data set. Most 
measurements are obtained at high substrate concentrations [S], and hence the data is 
clustered around small values of 1/[S]. Thus, a fit is performed over a limited range of 
spatially distributed data points. Furthermore, at small values of [S], small errors in Vo 
propagate into large errors in 1/Vo and hence large errors in Km and Vmax.  To circumvent 
these pitfalls nonlinear regression analysis can be used in which the data is directly fit to a 
Michaelis-Menton like equation.   
 Nonlinear regression is a form of analysis where a function which has nonlinear 
parameters, depends on more than one independent variable. This form is best used for 
enzyme kinetics due to the problems mentioned above. Actual constants of Km and Vmax 
are not determined accurately by the reciprocal Line-Weaver Burke plot. The values for the 
slope and intercept are not the most accurate determination of the variables. The program 
entitled GraphPad Prism® which uses nonlinear regression analysis determined the 
constants for the data sets in these experiments.  
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1.7 Introduction to Crystallography 
X-ray crystallography provides the most detailed information available on the 
structure of molecules. A crystal is mounted between an X-ray source and an X-ray 
detector.  In an X-ray diffraction experiment, a high quality protein crystal of appropriate 
size is mounted on a goniometer. An x-ray source emits a directed beam of x-rays which 
bombard the crystal. The x-rays pass through the crystal however they are deflected in the 
process. These scattered x-rays are then recorded as a diffraction pattern on an imaging 
plate or detector. The crystal is rotated on the goniometer and this process is repeated. 
Using the angles and intensities of these diffracted beams, a crystallographer can produce a 
three-dimensional picture of the density of electrons within the crystal (Figure 12).  
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Figure 12:  General Schematic of X-Ray Crystallography 
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In an x-ray scattering experiment, a single diffraction pattern is insufficient to 
determine a crystal structure. The crystal must be rotated 360 degrees with an image 
recorded at several intermediate steps to get enough data to solve the structure. There are 
only certain crystallographic planes from which constructive interference leads to strong 
diffraction. Each of these planes provides a distinct set of data regarding spatial 
arrangement of atoms in the crystal. Furthermore, every diffraction pattern corresponds to 
a different image of the electron density map and each spot in the diffraction pattern 
corresponds to a different type of variation in the electron density. The electron density 
maps are related to diffraction data by a Fourier transform.  
A Fourier transform is used to find the electron density from the diffraction pattern. 
This transform takes as input structure factors for each spot and their corresponding 
frequencies. The structure factor is proportional to the square root of the measured spot 
intensity and the frequency corresponds to the location of the spot in the diffraction 
pattern. Unfortunately, only the absolute value is available. Hence, additional information 
is necessary to determine phases and thus electron density maps. The following are 
common ways to solve the phasing problem of crystallography: Heavy Element 
Replacement, Anomalous Dispersion, Molecular Replacement (29). 
 
 
 
 
30 
1.8 Specific Aims of the Research 
 
 A.) To clone and characterize Mycobacterium Tuberculosis trmD gene.  
We will clone the trmD from Escherichia coli into an appropriate expression 
vector. Protein made in this vector will display an added N terminal his tag sequence 
permitting rapid purification of recombinant protein using Ni affinity column technology. 
To establish that the cloned gene product is in fact a tRNA methyl transferase, synthetic 
tRNA1
Leu
 substrate which contains G37 and G36 residues in the molecule will be 
employed. It has been shown previously that this serves as a substrate for several TrmD 
proteins. This will involve the determination of Km and Vmax values at various 
concentrations of both S-adenosyl methione and tRNA. We will be able to compare these 
values to that of other orthologues of TrmD.   
Once protein is obtained and shown to be a bona fide TrmD methyltransferase, we 
will first determine its oligomeric structure and demonstrate whether or not it will exist in 
solution as a homodimer.  All other TrmD proteins so far obtained have been shown to be 
dimeric (22). 
 
B.) To Crystallize Mycobacterial TrmD protein, and ultimately obtain the 
crystal structure. Initial crystal screens will be done using Hampton® general screening 
kits. If crystals are obtained, conditions will be optimized and diffraction studies will be 
carried out in collaboration with Dr. Martin Safo.  Once diffraction data is obtained of 
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sufficient resolution, attempts to solve the structure will be carried out using Molecular 
replacement programs available to us. 
C.) Ultimately, if a structure is obtained attempts to develop inhibitors of the 
enzyme will be initiated. This however, maybe beyond the scope of this study, but 
certainly a structure will facilitate this effort for rational drug design. In addition, with the 
protein in hand, other high throughput screens for inhibitors could be carried out.  
 
Chapter 2: Materials & Methods 
Materials: 
 The Novagen ligation-independent cloning vector was used for cloning and 
expression of M. tuberculosis gene DNA into suitable Eschericha Coli host cells. The 
oligonucleotides necessary for PCR amplification of trmD sequences  were ordered from 
Integrated DNA Technologies ®.  Using these oligonucleotides, Finnzymes Phusion High-
Fidelity Polymerase Chain Reaction (PCR) Master Mix® was used to amplify the desired  
trmD sequence from genomic DNA. QIAquick® Gel Extraction Kit was utilized to purify 
DNA from the agarose gels used to isolate amplified gene sequences.  Ampicillin was 
obtained from Sigma® and isopropyl β-d-thiogalactopyranoside (IPTG) was obtained from 
Molecula®.  LB broth growth media was purchased from Fisher and Sigma®. NovaBlue 
GigaSingles Competent Cells were purchased from Novagen®. Plasmid DNA was purified 
using the QIAprep Miniprep® kit was ordered from Qiagen. The DNA Core laboratory 
3700xl machine for sequencing located in Sanger Hall, MCV campus was utilized. 
Sonication was used to disrupt cells at a small scale and French Press was used for larger 
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preparations. Microcolumn® Nickel-NTA columns were used for the pilot scale batch of 
protein.  
Methods: 
2.1 Cloning 
The trmD gene from Mycobacterium tuberculosis was isolated from genomic DNA 
of the MtB CDC1551 strain (gene ID 925304/ accession number is NP_337486.1). This 
was provided to us by the laboratory of Dr. John Hackett.  The pET46 EK/LIC ligation-
independent cloning system was utilized for cloning (Novagen®) (Figure 13a).  Ligation-
independent cloning (LIC) exploits the 3’ to 5’ exonuclease activity of T4 DNA 
polymerase to strip nucleotides from a specific gene. This process continues until the 
polymerase utilizes and inserts a single dATP, which has been included in the reaction 
mixture. At this point, the polymerase activity of the enzyme overrides the exonuclease 
activity terminating the excision process and thus providing long sticky ends 
complementary to the overhangs in the LIC vector (Figure 13b). The resulting nucleic acid 
is readily introduced into the vector through a short annealing step, circumventing the 
ligation process. The pET46 vector contains an N-terminal His-tag expresses protein under 
the control of the T7lac promoter. Since the host cell contains an inducible RNA 
polymerase gene, and a lac operator, repressor system, IPTG addition leads to expression 
of the trmD gene. Furthermore, this vector contains kanamycin and ampicillin resistance 
genes for selection of transformed cultures.  
 Forward and reverse primers were specifically designed for expression using 
Novagen’s EK/LIC system. To ensure optimal function, primers were chosen which have 
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an absence of dimerization capability and avoid primer self-complementarity which may 
result in secondary structure formation. The following properties were used when 
designing the primers: 17-28 bases in length, Tm between 55-65°C, absence of 
dimerization capability (avoid primer self-complementarity which form secondary 
structures), and should have a 50-60% GC rich base ration (23). The designed primers are 
as follows:  
UPSTREAM:  5’-GACGACGACAAGATGCGCATCGATATCGTGACGATCTTC-3’                             
DOWNSTREAM:  5’-GAGGAGAAGCCCGGTCTAGTCGGGGTGGGACAG-3’  
Amplification was performed using the Phusion High-Fidelity Polymerase Chain 
Reaction (PCR) Master Mix (New England BioLabs). Following PCR amplification, the 
DNA was purified on an agarose gel and extracted using an alkaline ethanol method via 
the QIAquick® Gel Extraction Kit. 700 base pair bands were clearly detectable in 
duplicate wells as judged by DNA standards. These DNA bands were next treated with T4 
DNA polymerase, which exposes single stranded complementary sequences.  
The isolated DNA fragment was annealed with the pET-46 vector (Figure 13a) 
which comes with exposed complementary strands. Next the mixture of vector and insert 
was mixed with competent NovaBlue GigaSingle® cells. NovaBlue is an E. coli K-12 
strain and has high transformation efficiency with blue-white screening capability and recA 
endA mutations. Cells were provided in a 50 μl single-use volume tube and stored at -
70°C. Consequently, 250 μl of SOC media, provided in the kit, was added to the 
GigaSingle tubes. The tubes were incubated at 37°C while shaking at 250 rpm for 60 
minutes prior to plating on ampicillin medium. Selection for transformants was carried out 
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by plating cells mixed with vector and annealed insert on agar plates containing 50 μg/ml 
ampicillin. Plates were set on the bench for several minutes to allow excess liquid to be 
absorbed, inverted and incubated overnight at 37°C. Ten transformant colonies were 
picked from the agar plate and using a sterile toothpick and each were transferred to a 0.5-
ml eppendorf tube containing 50 μl sterile water and vortexed to disperse the cells. All 
tubes were placed in boiling water to lyse cells and denature DNAases, then centrifuged at 
12,000 x g for 1 minute to remove cell debris.  
A PCR reaction mixture was setup using PCR-grade water, dNTPs, upstream 
primer, downstream primer, 10X NovaTaq Buffer with MgCl2 and NovaTaq DNA 
Polymerase. Positive and negative controls were also included in the procedure. The cycles 
for PCR were repeated 35 times for the purpose of amplifying the plasmid. An agarose gel 
was made including DNA from all 10 clones isolated, a positive control and negative 
control and one well for the DNA 100 base pair ladder.  Phusion High-Fidelity Polymerase 
Chain Reaction (PCR) Master Mix was used to make a PCR product. PCR conditions 
included: initial denaturation at 98°C for 30 seconds, denaturation at 98ºC for 10 seconds, 
annealing at 70°C for 30 seconds and final extension at 72°C for 10 minutes. The 
denaturation and annealing step continued for 35 cycles. The sample was then put into a 
1% agarose gel 1X TAE. QIAquick Gel Extraction Kit® using a microcentrifuge was used 
to separate purified DNA from agarose gel.  
 Next, DNA containing inserts as judged by analysis via gel electophoresis was 
purified and sent to the VCU DNA Core facility. Appropriate clones were inoculated in 
Luria Broth (LB) and grown for 5 hours at 37°C.  After this time, the tubes were 
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transferred to large tubes and centrifuged for 5 minutes. The liquid was discarded and the 
cell pellet was left intact. The QIAprep Miniprep® extraction kit was utilized to extract 
DNA from the LB media in a matrix band tube. Four DNA samples and the appropriate 
complementary DNA primers were sequenced at the DNA Core laboratory. DNA was 
sequenced using a 3700xl DNA Analyzer. The concentration of DNA utilized for 
sequencing was 100 μg/ml, and the concentration of DNA reverse and forward primers 
were 20 μg/ml. T7 polymerase for chain elongation and reagents for dideoxy sequencing 
reactions was provided by the Core laboratory. Data were sent via email as ASCII 
sequence files or raw data. Sequence Scanner® was used to view the electropherograms 
and the Expasy® website was used to compare the sequences. 
2.2 Expression 
 Initially, a small scale culture was processed to determine if any protein was being 
made by the selected constructs. Recombinant DNA from several clones were each 
transformed into Rosetta RS2 cells. These host cells provide rare tRNA species which 
might recognize rare codons in the cloned trmD gene DNA. Each transformation mixture 
was plated with chloramphenicol and ampicillin for positive selection. Chloramphenicol is 
added to maintain the second plasmid in the Rosetta strain which encodes the rare tRNA 
species. Ampicillin selects for the recombinant plasmid containing the trmD gene.  The 
plates were incubated overnight at 37°C. Isolated colonies were selected from plates and 
each inoculated into LB test tubes. The tubes were then incubated at 37°C for 3-4 hours in 
a rotary shaker (200 rpm). These tubes were added to 4 ml of LB media and inoculated for 
1 hour. Spectrophotometer readings were periodically taken until OD reading of 0.6 (at 
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600 nm) was achieved. The cells were then induced with 1mM IPTG and shaken in a 
rotary shaker (200 rpm) overnight at 18°C. Cells were harvested by centrifugation for 10 
minutes at 10,000 rpm at 4°C.  The cell pellets were suspended in resuspension or lysis 
buffer (300mM NaCl, 50mM pH 7.5 phosphate buffer, 10 % glycerol and 10mM 
Imidazole). Cells were disrupted using an Avestin Multiflex® cell disrupter. In all cases 
three passes through this automated French Press were carried out. Cell debris was then 
removed by centrifugation of the crude extract for 30 minutes at 15,000 rpm. The soluble 
supernatant was collected and microcolumn Nickel-NTA columns from Qiagen® were 
used for purification. Centrifugation and equilibration of extract through these commercial 
spin columns (6000 rpm for 1 minute) assisted in separating protein from cells. The 
columns were washed with 300mM NaCl, 50mM pH 7.5 phosphate buffer and 10mM 
imidazole. Protein was eluted with 300mM Imidazole, 10 mM NaCl and 50mM pH 7.5 
phosphate. An SDS (Sodium dodecylsulfate) PAGE gel was done to check for the presence 
of protein.  
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Figure 13a: pET-46 Ek/LIC Vector generated by program EZ PLASMID MAP V1.9®.  
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Figure 13b: Diagram of Ek/LIC strategy (Adapted from Novagen®) 
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2.3 Protein Purification 
Large scale protein expression was next performed. Each liter of culture broth was 
prepared by adding 25 grams of granular LB-Broth from Fisher to 1 liter of deionized 
water. After the media was autoclaved, ampicillin was added at a concentration of 50ug/ml 
and chloramphicol at a concentration of 25μg/ml. These were added because the E.coli 
BL-21 strain contains the pET-46 vector, which in turn has the Mycobacterium 
tuberculosis trmD gene and the ampicillin and the Rossetta strain contains the tRNA 
encoding plasmid selected and maintained in the stain by chloramphenicol resistance. The 
culture medium was then inoculated with an overnight 30 ml starter culture containing 
ampicillin and chloramphenicol. Four liters of media were grown to obtain protein. Cells 
were put in a shaker at 200 rpm at 37
o
C. Cultures were grown to an A
600
 of 0.6, then 
induced over night at with 1 mM isopropyl β-D-thiogalactopyranoside (IPTG) at 180C. 
Cells were harvested by centrifugation at 5,000 rpm and the pellet was resuspended in lysis 
buffer, which contained 300mM NaCl, 50mM pH 7.5 phosphate buffer and 10mM 
Imidazole. Cells were then frozen at -80
o
C for subsequent protein isolation and 
purification.  
 The cells were then lysed using the Avestin French Press machine at 20,000 psi. In 
all cases extracts were passed three times through the cell disruptor. Consequently, the 
crude cellular lysate was centrifuged for 30 minutes at a speed of 10,000 rpm. The crude 
extract was then loaded onto a Qiagen® Ni-NTA nickel column. TrmDz protein has a His-
tag that is therefore bound tightly by the Nickel-NTA agarose beads. Wash buffer was then 
passed through the column, which contains 300mM NaCl, 50mM pH 7.5 phosphate buffer 
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and 10mM imidazole. This step was performed to remove any non specific binding protein 
as judged by removal of all detectable OD from the column. Following this initial wash, 
TrmD protein was eluted from the column with elution buffer containing a high 
concentration of imidazole. Elution buffer contains 300mM Imidazole, 10 mM NaCl and 
50mM pH 7.5 phosphate. Washing and eluting protocols using gravity flow as outlined by 
Qiagen® were modified as follows: after extensive washing in buffer A, the column was 
washed in a buffer with lower salt (50mM phosphate buffer pH 7.5, 50mM NaCl, 250mM 
imidizol). Fractions were collected and protein concentration was estimated by measuring 
UV absorbance at 280nm. Peak fractions were pooled and analyzed for purity via SDS 
PAGE gels.  Next the samples were dialyzed overnight in (50mM Tris-HCl pH 7.5, 300 
mM NaCl, 5mM 2-mercaptoethanol, .5mM EDTA, and .04% Na-Azide) in the cold room.  
  
2.4 SDS Polyacrylamide Gel Electrophoresis (SDS Page) 
The SDS Page gel was prepared following the protocol generated by Laemmli (30). 
This gel has a 12.5% acrylamide separating gel and a 4.1 % stacking gel. A gel is 
generated with a 10x10 cm gel rack with a thickness of 0.75mm.  The protein samples to 
be analyzed are prepared by first adding appropriate amounts of 2X SDS loading buffer, 
which is made up of Tris buffer, SDS, glycerol and the reducing agent beta 
mercapoethanol, to the protein solution containing about 10-100μg protein. Then the 
protein was denatured by placing the samples into boiling water for 2-5 minutes. The SDS 
PAGE running buffer contained Tris-base, glycine and SDS.  One liter of 5X stock 
solution of the protein running buffer contains 15 grams of tris-base, 72 grams of glycine 
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and 5 grams of SDS. A 1X solution of this mixture is used to perform SDS Polyacrylamide 
Gel Electrophoresis. Approximately 15μl of sample solution was loaded into each well, 
then electrophorized at a constant voltage of ~50mV at room temperature. The 2X loading 
buffer contains bromophenyl blue, which determines the progress of electrophoresis. As 
soon as this dye reached the bottom of the gel, electrophoresis was stopped.  Gels were 
then  stained with coomassie brilliant blue solution, containing 50% H20, 40% methanol 
10% acetic acid and (v/v) 0.05% coomassie brilliant blue R250, ideally it is allowed to sit 
over night and subsequently destained with a destaining solution composed of 70% water, 
20% methanol and 10% acetic acid.  
 
2.5  Native Gel Electrophoresis 
 "Native" or "non-denaturing" gel electrophoresis was performed in the absence of 
SDS. In the SDS-PAGE the electrophoresis mobility of proteins depends primarily on their 
molecular mass, however in the native PAGE gels mobility depends on both the protein's 
charge and its hydrodynamic size. The resolving gel contained 10% acrylamide and Bis-
acyalimde added to achieve a ratio of 1:37 and .4M Tris-HCl pH 8.8. The stacking gel 
contained 7.5% acylamide and Bis-acrylamide was added to achieve a ratio of 1:37 and 
0.25M Tris-HCl pH 6.8. Polymerization of gel was achieved by the addition of 10ul of 
Tetramethylethylenediamine (TEMED) and 40ul of 15% ammonium persulfate. Sample 
buffer contained 100mM Tris-HCl buffer pH=6.8, 200 mM DTT, 20% glycerol and .1% 
bromophenol blue. The electrophoresis buffer contained 3g of Tris base and 14.4 grams of 
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glycine in one liter. The final pH was 8.3. Protein stain solution consisted of .05% 
Coomassie Brilliant Blue R, 50% Methanol, 40% water and 10% Acetic Acid (v/v). 
Destaining solution contains 50% Methanol, 40% water and 10% Acetic Acid (v/v).   
2.6 Methods of Kinetic Assays 
 
Two assays were developed to assess TrmD kinetics as well as inhibition. In the 
process of performing a kinetic assay, the velocity of the reaction is measured at a series of 
incrementally increasing substrate concentrations. This permits determination of Km and 
Vmax.  For these assays, the concentration of enzyme and cofactor were optimized. In the 
case of TrmD, the substrates are a G36G37 tRNA (tRNA1
Leu
) and S-adenosyl-methionine 
(AdoMet).  Enzyme activity was determined using a modification of the method developed 
by Hjalmarsson et al. (31). The assay conditions were optimized to ensure proper function 
of the enzyme for the measurements conducted. 50 µl of reaction mixture consisted of 50 
µM cold SAM, 1.8 µl of 
3
H-SAM (specific activity 85 Ci/mmol), buffer (0.1 M Tris-HCl  
pH 8.5, 1 mM DTT, 0.1 mM EDTA, 6mM MgCl2, 24 mM NH4Cl, 20 µg of enzyme and 
variable amounts of E. coli  tRNA1
Leu
 transcripts (Figure 14). Using these conditions as a 
starting point the parameters were optimized for the MtB TrmD. tRNA synthesis was 
performed using a combination of methods. The protocol described in Holmes et al. (32) 
outlined a basis for the procedure. Template preparation involved the growth of pUTL4 in 
XL1-Blue E. coli cells obtained from Stragene. Plasmid purification was carried out using 
the Qiagen Plasmid Giga kit® followed by DEAE batch column chromatography. Using 
these methods tRNA was produced and supplied by M. Palesis.  
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To ascertain an optimal enzyme concentration for the assay, tRNA and AdoMet 
concentrations were added in excess and the enzyme concentration varied. Activity was 
measured in a time course spanning 25 minutes in a 5 minute interval. Once an optimal 
enzyme concentration which ensured linear methylation over the time course of the assay 
(20 µg of protein per assay), a second series of experiments were performed in which the 
concentration of SAM was varied in the presence of excess tRNA concentration to allow 
determination of Km and Vmax for SAM. The concentrations of SAM employed  were 45 
µM, 65 µM, 150 µM, 155 µM. 5 minute assays were carried out. The values of [tRNA] 
were 5 µM, 15 µM, 18 µM, 58 µM, 78 µM and 65 µM set through a time course assay of 5 
minute intervals between concentrations. The enzyme reaction was allowed to proceed for 
4 minutes. Following 4 minutes, the reaction was stopped by adding 1 ml of ice cold (10%) 
tri-chloro-acetic acid (TCA). After 15 minutes, all of the tRNA is completely precipitated, 
and the reaction mixture is loaded onto a GF-A Whatman filter paper. Vacuum filtration 
and washing with TCA was done to remove excess labeled free AdoMet. The filter paper is 
then dried with 100% ethanol and activity is measured (Figure 14). The filter paper will 
retain the radioactively labeled tRNA which then can be counted using the Packard Tri-
Carb 1500 Liquid Scintillation Analyzer. Conversely, to obtain the Km and Vmax for the 
tRNA excess SAM and the tRNA concentration varied. The time course of the reaction 
was followed to ensure the rate being observed in these assays was linear and 
representative of the initial reaction rate. Km and Vmax were calculated by using the 
program Prism® which utilizes non-linear regression analysis.  
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A preliminary inhibitory assay was also conducted on this enzyme. The same 
procedure as clone for the kinetic assays was utilized (Figure 14) except that 156 uM of 
inhibitory compounds were included in the reaction mixture. The two inhibitory 
compounds used were Congo Red and 4,4'-bis(1-anilinonaphthalene 8-sulfonate) (Bis-
ANS) (Figure 16). Both these compounds are hydrophobic and have proven to be 
inhibitors of the E. coli TrmD protein (unpublished, M Palesis).  
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Figure 14: General Schematic for the kinetic assay reactions performed for varying 
substrate concentration 
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2.7 Methods of Crystallography 
 The most common setup to grow protein crystals is by the hanging drop technique. 
A few microliters of protein solution are mixed with an about equal amount of reservoir 
solution containing the precipitants. A drop of this mixture is put on a glass slide which 
covers the reservoir. As the protein/precipitant mixture in the drop is less concentrated than 
the reservoir solution (protein solution with the reservior solution about 1:1), water 
evaporates from the drop into the reservoir. As a result the concentration of both protein 
and precipitant in the drop slowly increases, and crystals may form (Figure 16). Simply 
put, the hanging drop method differs from the sitting drop method in the vertical 
orientation of the protein solution drop within the system. It is important to mention that 
a. 
b. 
Figure 15: Structure of Inhibitors 
a.- Congo Red  
b.- 4,4'-bis(1-anilinonaphthalene 8-
sulfonate) or Bis-ANS 
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both methods require a closed system, that is, the system must be sealed off from the 
outside using an airtight container or high-vacuum grease between glass surfaces (Figure 
17). Even smaller volumes can be handles in button-like dialysis cells which are often used 
in x-ray crystallography. A dialysis membrane with a cutoff molecular weight value is 
used to seal the buttons. However, it is important that the buttons are completely filled and 
without air bubbles which otherwise can prevent the contact of the solution with the 
dialysis membrane.   
  
 
 
Figure 16: Hanging Drop Diagram 
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Figure 17: Sitting Drop Diagram 
 
A seed provides a template for the assembly of molecules to form a crystal with the 
same characteristics as the crystal from which it originated. It is important to differentiate 
the process of crystal growth from nucleation. In general, the degree of supersaturation 
required for nucleation is higher than that required for crystal growth. Normally, during 
aggregation, there is an equilibrium between the formation of ordered nuclei (reversible) 
and the formation of fprecipitate (irreversible). When crystal seeds are added, the 
equilibrium can shift towards crystal formation, and avoids the random nature of 
spontaneous nucleation. There are three commonly used types of seeding: Microseeding 
which adds very small pieces of crushed protein crystals to the crystallization drop; 
Macroseeding which adds an intact, already grown crystal to the crystallization drop; 
Streak seeding which is similar to microseeding but uses a fine hair (often a cat’s whisker 
or horse hair is best) to pick up small protein crystal fragments.  
 Mounting of most protein crystals on an x-ray diffractometer is done at cryogenic 
temperatures, usually around 100K. A small nylon loop is used to pick up a crystal, 
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immerse it a cryoprotectant solution for a short period of time, and then either plunge it in 
liquid nitrogen (or sometimes liquid propane), or place it directly on the goniometer head 
in a stream of cold nitrogen gas.  
Crystals of M. Tuberculosis TrmDz without AdoMet bound grew in sitting drop 
trays at 25°C at room temperature. The concentration of the protein was 12.4 mg/ml in 50 
mM Tris-HCl pH 7.5, 0.1 M NaCl, 1 mM DTT. Drops were a 2ul:2ul ratio mixture of 
protein to precipitant. Hampton Research Crystal Screening 1 was used to screen reagents. 
A total of 48 reagents were included in the kit. The 24 well VDX48 crystal trays with 
sealant from Hampton Research were utilized for the screens. Siliconized Glass Cover 
Slides from Hampton Research allowed a droplet to be suspended in a position which 
provides near optimal conditions for vapor diffusion. The cryoprotectant used was 25% 
glycerol for each crystal shot.   
Initially, attempts to crystallize the   M. Tuberculosis TrmD protein  were done 
without AdoMet in sitting drop trays at 25°C.  The concentration of the protein usedwas 
12.4 mg/ml in 50 mM Tris-HCl pH 7.5, 0.1 M NaCl, 1 mM DTT. Each Drop contained  
2μl of precipitant and 2 μl   of protein solution.  Initially,  Hampton Research Crystal 
Screening kit 1® was used to screen reagents. This kit  provided  48 separate precipitant 
solutions.  Hampton Research® (24 well) VDX48 crystal trays with sealant were utilized 
for the screens. Siliconized glass cover Slides from Hampton Research  were employed as 
well. Most of the following steps were carried out with the help Dr. Martin Safo in the 
Institute. In all cases promising crystals from selected wells were suspended in 25% 
glycerol plus the correct selected precipitant.   
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 Diffraction experiments were performed on a Raxis IV (Rigaku Americas Co.) 
diffractometer under  Nitrogen cryo-cooling conditions at -100 K. Crystals were swiftly 
taken out of the mother liquor in the well using a nylon loop then flash-frozen under a 
stream of liquid nitrogen on the goniometer head. Indexing of initial frames showed 
different forms for buffer conditions. The diffractometer was programmed to collect 0.5° 
oscillation frames from φ angles 0° to 180° at 0.5° intervals (360 frames) and an exposure 
time of 10 minutes. The crystal-to-dectector distance was adjusted to 130mm. Once the 
data collection was complete, the data was integrated using the d*trek program under the 
CrystalClear® software package (Rigaku Americas Co). The program entitled Crystal-
Clear collects and integrates the reflection of spots. 
 
Chapter 3 
 
3.1 Results of Cloning 
 
As outlined in the previous section trmD sequences have been cloned and verified 
by sequence analysis.  Using the protocols and stated in the methods section, forward and 
reverse primers were designed then used with a Finnzyme Phusion High-Fidelity PCR 
Master Mix®  to PCR trmD sequences from genomic DNA. Once PCR was performed, 
an agrose gel confirmed the presence of amplified trmD DNA (Figure 18).   In figure 18  
700 bp bands are seen as judged from a 100 bp DNA ladder which corresponds nicely 
with the calculated size of the amplified gene (MW 693).  Consequently, the DNA was 
extracted and cloned into a pET-46 EK/LIC vector. Once cloned host cells were 
transformed as outlined above and ten colonies selected for analysis. DNA extracted from 
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each of these clones was analysed by analytical PCR which should determine if trmD 
inserts were present.  Inserts were found in colony numbers 2, 6, 8, 10 (Figure 19).  
DNA was prepared from clones 6 and 8 which had been shown to contain trmD 
inserts as judged by PCR amplification.   Plasmid DNA from these two clonal isolates was 
sent to the DNA Core laboratory for sequencing. The results from the sequencing lab 
reported that all sequences were in-frame and contained no mutations. The sequences for 
samples 6 and 8 were found in the first frame (Figure 20). These samples were used for 
protein expression and named TrmDz1 and TrmDz2, respectively. Utilizing the  program  
Sequence Scanner v1.0®  an actual sequence readout from the 3700 sequencer is shown 
(Figure 21).  
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Figure 18: Agarose gel of PCR product: leftmost lane; 100 base pair (bp) ladder, Sample 
and Sample 2. Sample 1 and 2 contained 20ul of PCR product.  The red arrow indicates 
where the 700 base pair standard runs.  
 
 
 
 
 
700 BP Band 
BP Ladder  Sample 1   Sample 2 
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Figure 19: Agarose Gel electrophoresis of PCR amplified trmD gene inserts. 
 Left to Right: Molecular Weight standards Ladder (L), 2, 6, 8, 10 and positive control 
contained inserts.  
 
 
 
 
 
 
 
 
 
L   1    2  3 4 5    6   7  8  9      10  - + 
54 
Mycobacterium Tuberculosis trmD CDC1551 
Amino Acid Sequence  
A. V R I D I V T I F P A C L D P L R Q S L P G K A I E S G L V D L N V H D L R 
R W T H D V H H S V D D A P Y G G G P G Met V Met K A P V W G E A L D E I 
C S S E T L L I V P T P A G V L F T Q A T A Q R W T T E S H L V F A C G R Y E 
G I D Q R V V Q D A A R R Met R V E E V S I G D Y V L P G G E S A A V V Met 
V E A V L R L L A G V L G N P A S H Q D D S H S T G L D G L L E G P S Y T R 
P A S W R G L D V P E V L L S G D H A R I A A W R R E V S L Q R T R E R R P 
D L S H P D Stop  
 
Sample 8 Forward Primer:  
B.5'3'Frame1 
P A C L D P L R Q S L P G K A I E S G L V D L N V H D L R R W T H D V H H S 
V D D A P Y G G G P G Met V Met K A P V W G E A L D E I C S S E T L L I V P 
T P A G V L F T Q A T A Q R W T T E S H L V F A C G R Y E G I D Q R V V Q D 
A A R R Met R V E E V S I G D Y V L P G G E S A A V V Met V E A V L R L L A 
G V L G N P A S H Q D D S H S T G L D G L L E G P S Y T R P A S W R G L D V 
P E V L L S G D H A R I A A W R R E V S L Q R T R E R R P D L S H P D Stop T 
G L L L K S R V W Stop R N R C C E I Stop T P A H G L V Y Stop R S L I N L G 
C C H R Stop A I T S I T P W G L Stop T G L E G F F A E R R N Y I R I G E W D 
A P C S G A L S A A G V V V T R S V T A T L A S A L A P A P F A F F P S F L A 
T F A G F P R Q A L N R G L P L G S D L V L Y A L D P K N Stop L G D V T Y G 
H R L I D V F A F D V E S T F L I W T L S L T H S P I S I Y P Stop I K E L R I A S 
K N G A D Y K L R D 
 
Figure 20: Sequencing Results a.-putative amino acid sequence for annotated gene, (gene 
ID 925304/ accession number is NP_337486.1) b.- Amino acid sequence derived from the  
DNA sequence of clone  8. Shown in red is the deduced amino acid sequence from one of 
the reading frames of this sequence.  
 
 
 
Figure 21: Screenshot of Sample 8 DNA sequence using Sequence Scanner Program® 
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3.2 Expression and Purification 
 
 Clones 6 and 8 which have been designated TrmDz1 and TmDz2 were expressed at 
a pilot scale to determine if protein of the correct size had been made. As can be seen in 
Figure 22, protein of the correct size can be seen for both clones 6 and 8.   Since this is a 
SDS gel then this should reflect the monomer molecular weight of the subunits for this 
TrmD protein. A monomer form with a molecular weight of approximately 25 kDa is seen 
as judged by molecular weight markers incorporated in the gel. The actual size of the 
TrmD protein should be larger than 25 kDa since there is now a His-tag sequence present 
at the amino terminus. The gel mobility reflects these added residues.  
       Since the protein gels displays bands of the correct size from both clones, a larger 
scale expression of TrmDz2 was initiated.  A two liter volume of cells was induced with 1 
mM IPTG once the OD at 600 nm reached 0.8. The liters were incubated in the shaker at 
18°C at a speed of 200 rpm overnight.   
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Figure 22: Protein Gel of MtB TrmD Sample 1 is TrmDz1 and Sample 2 is TrmDz2. 
Order of wells: protein after incubation trmDz1 (Cell Extract 1), protein after incubation 
trmDz2 (Cell Extract 2), protein centrifuge trmDz1 (Protein Centrifuge 1), protein 
centrifuged trmDz2 (Protein Centrifuged 2), cell lysate z1 (Cell Lysate 1), cell lysate z2 
(Cell Lysate 2), protein ladder (Protein Ladder), flow through z1 (Flow Through 1), flow 
through z2 (Flow Through 2), wash z1 (W1), wash z2 (W2), elution z1 (EL1), elution  z2 
(EL2). Arrow points to 25kDa on the Protein Ladder.  
25 kDa 
  CE1  CE2  PC1   PC2  CL1 CL2   PL   FT1 FT2  W1   W2    EL1   EL2 
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3.3 Protein Purification 
As outline above the cultures were centrifuged and the cells lysed using the French 
Press. Crude extracts were clarified by centrifugation, then purified using Ni-NTA 
columns as outlined above. Figure 24 shows stained proteins in a 12% SDS Acrylamide 
gel. In this case BL21(DE3) host cells were used and excellent expression was achieved. 
Approximately 9 ml of purified protein was obtained containing 12 mg/ml of TrmD 
protein.  As can be seen in all appropriate wells. A single band of 25 kDa was observed on 
the SDS-PAGE gel (Figure 23).   In  these cases, very high levels of TrmD protein were 
added (25 μg per well) to show the degree of purity of the protein.  
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Figure 23: SDS protein gel of purified Mycobacterial TrmD protein. Lanes from left to 
right: Protein Ladder (PL), Cell Lysate (CL1), Protein (P1), and Protein after Dialysis 
(D1). Sample CL2, P2 and D2 are repeats of the left side. In the case of purified TrmD 
samples approximately 25 μg of TrmD protein were loaded.  
 
 
 
 
PL CL1       P1              D1         PL2         CL2          P2            D2 
25 kDa 
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Figure 24: Native Gel with purified MtB TrmD protein concentrations in designate lanes: 
Sample 1 (5ug), Sample 2 (4ug), Sample 3 (3ug) and Sample 4 (1 ug). The first well is the 
Protein ladder. The bands all line up to the 50 kDa line of the ladder.   
 
 
 
 
        PL         Sample 1      Sample 2    Sample 3 Sample 4 
50 kDa 
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It has been shown that all TrmD protein orthologues so far studied are homodimers 
(22). The putative subunit molecular weight of this enzyme was consistent with that of 
other TrmD proteins. In order to determine whether or not this enzyme is dimeric like 
other TrmD proteins, samples of Mycobacterial trmD protein was electrophoresed through 
Polyacrylamide gels without SDS or other denaturants. As shown in figure 24, samples run 
show a molecular weight of approximately 50,000 daltons which is consistent with a 
dimeric form of the enzyme.  
3.4 Results of Kinetic Assays 
 The Vmax for SAM was .02818 nM product/min/ug of protein and  the Km was 26 
µM (Figure 26). The methylation kinetics of the tRNA displayed a Vmax of .001024 nM 
product/ min/ µg protein and a Km of 41.80 µM (Figure 27).  Extensive kinetic analyses 
have been performed on the E. coli TrmD and these results can be compared to that of the 
MtB TrmD. Previous data has shown that the E. coli TrmD has a Km value of 5 µM for 
tRNA methylation and 8 µM for SAM methylation (32). A turnover number was 
calculated and compared with that of MtB TrmD (Table 2). The turnover number was 12.6 
molecules of product/molecule of enzyme/minute for E. Coli TrmD and 0.14 molecules of 
product/molecule of enzyme/minute for the MtB TrmD. This result reveals that the E. coli 
enzyme is much more active than the MtB enzyme. In the inhibition studies, both 
compounds at 156 µM proved to significantly diminish the activity of MtB enzyme. 
Activity drastically dropped from a 13000 CPM
3
H to a mere 449 CPM
3
H for the Bis-ANS 
and 330 CPM
3
H for the Congo Red assays. Thus, these compounds are potent inhibitors 
for this enzyme.  
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Figure 25: Kinetic Assay Data of enzyme, TrmDz, and varying concentration of substrate, 
SAM. 
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Figure 26: Kinetic Assay Data of enzyme, TrmDz, and varying concentration of substrate, 
tRNA. 
 
 
Table 2: Table comparing E. coli and MtB TrmD turnovers 
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Figure 27: Graph representing activity of enzyme in the presence of inhibitors Bis-ANS 
and Congo Red.  
 
3.3 Results of Crystallization 
As previously mentioned, all crystals were grown at room temperature. There were 
several conditions where crystals were observed. The first was 30% Polyethylene Glycol 
(PEG) 4000, 0.1M Tris-HCl, 0.2M Lithium Sulfate (Figure 28 a,b). The protein 
concentration was 12.4 mg/ml. Microcrystal showers were observed under this condition 
after one week. Optimization of this condition was performed. Larger, better crystals were 
never produced.  
The second condition which produced crystals was 1.0M Ammonium Phosphate, 
0.1M Na Citrate pH 5.6 (Figure 28 c,d). One single crystal formed in this well after three 
weeks. A resolution of 4.9 Å was observed for this crystal formation. The spot intensity 
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dropped after 7.8 Å. The crystal shape was hexagonal. The unit cell was a=b=119.765 Å, 
c=172.29. After optimization of conditions, larger crystals were observed in 0.8M 
Ammonium Phosphate 0.1 M Na Citrate pH= 5.6 and 0.9M Ammonium Phosphate 0.1M 
Na Citrate pH=5.6 (Figure 28 f,g). However, after diffraction it was found that the 
resolution was poor for this crystal formation, 3.5 Å (Table 3).  
Two other conditions found were 20% Polyethylene Glycol (PEG) 3350 0.2M di-
Ammonium Citrate and 20% Polyethylene Glycol (PEG) 3350 0.2 M Calcium Acetate 
(Figure 28h). However, even after optimization larger crystals were not produced.  
The best condition for growth was 1.2M Sodium Formate, 0.1M Na Acetate pH 4.6 
(Figure 28e) and many crystals were grown under these conditions. Crystals formed in 
approximately one week period. Multiple single crystal formations were seen in each 
well. These crystal formations were shot many times. The first had a resolutions of 4.5 Å. 
The initial shape was hexagonal and the hypothesized space group was P622. However, 
several different shapes were seen in each well. The next attempt had a resolution of 4.0 Å 
and was triclinic. The unit cell for all these crystals shot were a=b=119.765 Å, c= 172.29. 
The water content was 65%. Ultimately, the crystal formations yield a space group of 
P321. The unit cells were a=b=207.88, c=172.1269. These crystals yielded a resolution of 
2.9 Å. However, using Matthew’s coefficient, 12 residues were found per asymmetric 
unit. A total of 300 frames were collected for the last attempt. Using Crystal Clear® the 
data was integrated and an R factor of 12.5% was observed. The diffraction pattern is 
shown in Figure 29.   
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Figure 28: Picture of crystal formations a, b- 30% PEG 4000, .1M Tris HCl, .2M Lithium 
Sulfate c, d- 1.0M Ammonium Phosphate, .1M Na Citrate pH 5.6 e.- 1.2M Sodium 
Formate, 0.1M Na Acetate pH 4.6 f.- .8M Ammonium Phosphate .1 M Na Citrate pH= 5.6 
g.- .9M Ammonium Phosphate .1M Na Citrate pH=5.6 h.- 20% PEG 3350 .2 M Calcium 
Acetate 
 
 
a. b. c.
d.
e.
f.
g. h.
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Table 3: Summary of crystal diffraction data for MtB TrmDz 
 
 
 
Figure 29: X-Ray Diffraction Pattern of 1.2M Sodium Formate, 0.1M Na Acetate pH 4.6 
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Chapter 4 
4.1 Discussion 
 TrmD functions catalytically as a ternary complex comprised of the trmD enzyme, 
a tRNA substrate and the AdoMet cofactor. In the case of the E. Coli enzyme, the binding 
of tRNA and AdoMet are not co-dependent, and the enzyme exhibits random sequential 
kinetics. Studies in the Holmes lab suggest that only one AdoMet is bound not two in the 
S. pneumonia TrmD protein (unpublished, M Palesis).  
 The kinetic assays of methylation done here show that the activity of methylation 
occurs much slower in MtB than in the E. coli TrmD. The turnover number relates the 
amount of product methylated per a unit of time, per molecule of enzyme. MtB is an 
aerobic bacterium that divides every 16 to 20 hours, an extremely slow rate compared with 
many other bacteria, which usually divide in less than an hour (5). Thus, the rate at which 
methylation of tRNA occurs is important for maintaining tRNA methylation which is in 
turn required for error free protein synthesis. The data presented here only provide an 
initial study of the kinetics of the TrmD from TB. More extensive studies need to be 
performed to properly compare rate constants of this enzyme to other known trmD 
organisms. 
It is clear that the TrmD protein is an important target for antimicrobial agents 
because it has been shown to be essential in a number of eubacterial forms and is a protein 
unique to eubacteria. All cellular forms contain enzymes that catalyze the AdoMet 
dependent methylation of tRNA molecules at G37, a modification that prevents frame 
shifting (22). Whereas most missense errors do not eliminate the activity and stability of 
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proteins, frameshift errors which are the result of an inactive trmD gene are detrimental for 
cellular viability (27). It is likely that maintenance of proper reading frames would be a 
strongly conserved property of all cellular forms, and a prerequisite for the emergence of 
the three domains of life, namely Archaea, Bacteria and Eukaryotes (7). Thus, this enzyme 
is part of the minimal set of gene products required for the evolution of all cellular forms 
(25). Mutational analysis performed in two bacterial species confirmed that a defect in the 
protein will cause the bacterium to grow more slowly (E. coli) or be lethal to the organism 
(S. pneumonia) (21). Deficiency of TrmD appears to have a global effect on cell 
physiology. Bjork et. al. observed changes in carbon source metabolism and resistance or 
sensitivity to amino acid analogs (26). In particular, lack of enzyme affects metabolism of 
thiamine and pantothenate (27, 28).   
This project included cloning, expression, characterization and crystallization of 
Mycobacterium tuberculosis trmD.  In the characterization experiments, kinetic assays 
and some inhibitor work were performed to compare this enzyme with that of previous 
data for other trmD orthologs determined by Holmes’s laboratory. We have not yet shown 
that TrmD is an essential protein in the Mycobacteria, and this should be done if we are to 
move ahead in the development of a new antimicrobial agent active against this organism. 
Other issues that are important to deal with will be permeability problems of any drug 
developed since the cell wall of Mycobacteria is very hydrophobic and relatively 
impermeable. Other barriers will involve defeating pump mechanisms that might exist. 
The enzyme was relatively easy to crystallize, and crystals were seen within one 
week under certain conditions.  Sodium formate crystals formed relatively quickly and 
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were the largest seen. Considerable time was spent optimizing conditions with this 
precipitant. It was observed that increasing protein concentration more than 22 mg/ml 
produced showers of micro-crystals. Decreasing the protein concentration less than 12 
mg/ml yielded no crystals. It was determined that a range of 12 to 20 mg/ml was optimal 
for obtaining large crystals under these conditions. Other techniques employed (Dialysis 
buttons, macro and micro-seeding) did not yield larger crystals. Magnesium was explored 
as a factor for obtaining better crystals because it is required for optimal catalytic activity 
for this enzyme.  Interestingly, magnesium actually prevented crystal formation. In 
previous TrmD crystal structures no magnesium was ever seen. Perhaps its role is in post 
tRNA interaction events such as base flipping in tRNA. Most previous TrmD proteins 
were crystallized with AdoMet bound to enzyme, but we found that the M. tuberculosis 
TrmD did not crystallize when AdoMet was added to protein samples at least under the 
methods used here. Attempts in adding AdoMet directly in protein mixture or adding 
AdoMet to protein and buffer mixture did not yield any crystals. Further work needs to be 
performed on producing crystals with ligand bound to enzyme. It will be important to 
obtain these co-crystals if inhibitors which bind this region are to be developed in order to 
gain insight into overall enzyme mechanisms. 
Other conditions for optimizing crystallization were explored to include 
temperature and pH. It appears that pH’s near neutrality is important for the crystallization 
of this protein. A reduced temperature of 10 ºC did not improve crystallization. If fact, no 
crystals were formed after a month of incubation under this condition. 
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Other precipitants were observed to crystallize the protein in the initial Hampton 
screen. Crystals were seen under the following conditions: 1.2M Sodium Formate, 0.1M 
Sodium Acetate pH= 4.6 (Figure 28e); 30% Polyethylene Glycol (PEG) 4000 0.1M Tris 
HCl pH=8.5 .2M Lithium Sulfate (Figure 28 a,b); 1.0 M Ammonium Phosphate 0.1 M 
Sodium Citrate pH=5.6 (Figure 28 c,d), 25% PEG 6000 .1M HEPES pH= 7.5; 20% PEG 
3350 0.2M Calcium Acetate (Figure 28h); 20% PEG 3350 0.2M di-Ammonium Citrate; 
40% PEG 200 0.1M MES pH=6.5 and 20% PEG 3350 0.2M di-Ammonium tartrate; 0.8M 
Ammonium Phosphate, .1M Sodium Citrate pH=5.6 (Figure 28f); and .9M Ammonium 
Phosphate, 0.1M Sodium Citrate pH=5.6 (Figure 28g). The following crystals were 
selected for subsequent X-ray analysis: 1.2 M Sodium Formate, 0.1M Na Acetate pH=4.6; 
1.0M Ammonium Phosphate, 0.1M Na Citrate pH=5.6; 20% Polyethylene Glycol (PEG) 
3350 0.2M Calcium Acetate.  
In the 1.0M Ammonium Phosphate 0.1M Na Citrate pH 5.6 (Figure 28c) buffer one 
single crystal formed after three weeks. The resolution was 4.9 Å for this crystal form. 
The spot intensity dropped after 7.8 Å and the shape was hexagonal. The unit cell 
dimensions were a=b=119.765 Å, c= 172.29. After repeated optimization attempts larger 
crystals were formed, however the larger crystals did not diffract.  
In the 1.2 M Sodium Formate .1 M Sodium Acetate pH=4.6 the unit cells were 
a=b=207.88, c=172.1269. Several crystals were analysed, and the final attempt with this 
condition yeilded a resolution of 2.9 Å which was the best resolution seen in these studies. 
The Programs Phoenix® and CCP4® were used to integrate the data. Using Matthew’s 
coefficient, 12 residues were found per asymmetric unit and the solvent content was about 
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57%. Matthew’s calculation estimates of the number of molecules per unit cell (Z). 
Because of this, the structure proved to be very difficult to solve. This is part of the 
symmetric object from which the whole is built up by repeats. During the last effort of 
crystallography another protein condition yielded large crystals, 20% PEG 3350 0.2M di-
Ammonium tartrate. The unit cell was again a=b=207.88, c=172.1269. This is similar to 
data for the sodium formate crystals.  
After obtaining similar results for two different buffer conditions it can be inferred 
that the enzyme itself does not pack properly. The number of molecules in the asymmetric 
unit helps define the crystal packing as non-Centro symmetric. This is a space group 
which lacks an inversion center. Center of Symmetry (or Center of Inversion) is a point 
through which an inversion operation is performed, converting an object into its mirror 
image. As a result of the high number of molecules per asymmetric unit the cell packing 
is affected. A crystal is a three-dimensional periodic arrangement of molecules. When the 
material precipitates from a solution, its molecules attempt to reach the lowest free energy 
state. The search for a minimum free energy, and as a consequence the regular packing of 
molecules in a crystal lattice, often leads to a symmetric relationship between molecules. 
Due to the number of residues per asymmetric unit “loose” binding occurs between the 
units. When the crystal does not have tight binding between units, packing issues arise 
and resolution of the crystal is also affected.  
   Another issue to consider is the cryoprotectant Glycerol was the only 
cryoprotectant used for crystals obtained. Initially, 20% glycerol was used to check 
diffraction of the sodium formate crystals. However, it was noticed that as the amount of 
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glycerol decreased, better resolution was observed. When collecting data for the last 
crystal, 10% glycerol was used in 20% PEG 3350 .2M Calcium Acetate. Other options to 
consider in the future involve trying different cryoprotectant conditions. A CryoPro® kit, 
which includes 36 conditions available, produced by Hampton Research Company, was 
considered for usage in the future.   
An alternative we contemplated for future work involved protein modification. One 
modification would be to remove the 6x His-tag from the protein. There are a number of 
kits and protocols to assist in removal of the His-tag. Another mutation would involve 
changing the amino acid sequence of the protein.  
Why then, does the mycobacterial trmD enzyme pose such problems in packing?  
One major difference exists from most other trmD genes.  The TrmD protein is 
substaintially shorter than the E. coli and most other TrmD proteins.  It has 231 amino 
acid residues whereas E. coli has 255 residues. Therefore the final alpha helix seen with 
the E. coli enzyme is absent from the Mycobacterial TrmD protein.  If for example the C 
terminus is a key stable contact point in crystals then other contact points may occur in the 
Mycobacterial TrmD creating packing problems. For example, now the mobile his tag 
sequences might create problems with the resulting heterogeneous packing that might 
ensue. If this is true it will be important to remove the His tag sequence by proteolysis and 
again attempt crystallization.   
The pdb files of the following trmD enzymes were all viewed and compared: 
Streptococcus pneumonia, Bartonella henselae, and Eschericha coli. After close 
observation of the residues within the asymmetrical unit, it was found that the missing 
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amino acids from the Mycobacterium tuberculosis organism greatly impacted the stability 
of the structure. The residues at the C-terminus played an important role in interacting 
between the residues of different lattices. Thus, packing of the crystal would be impacted 
if those important interactions did not occur. This may account for the problems of low 
resolution, diffraction and large numbers of residues per asymmetric unit.   
One possible approach for improving crystal packing could involve the removal of 
the His-tag which might introduce heterogenous packing. Alternatively, since many other 
trmDs have been crystallized with the His-tag it seems reasonable the C-terminus contact 
points were important. Therefore, if a terminal alpha helix were added to the TB protein 
then better packing might be achieved.    
In summary, we have initiated an extensive effort to obtain the crystal structure of 
an important drug target from a very important pathogen.  Considerable progress has been 
made which point the way towards a successful solution of the structure. 
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